PAQ Therapeutics

aid: paq-therapeutics
name: PAQ Therapeutics
description: 'PAQ Therapeutics is a clinical-stage biotechnology company headquartered at 100 Summit Drive, Burlington, Massachusetts,
  developing targeted protein degradation (TPD) medicines for KRAS-driven cancers. Rather than inhibiting the KRAS oncoprotein,
  PAQ''s autophagy-based degrader chemistry recruits the cell''s own natural degradation machinery to remove the protein outright,
  an approach the company applies to the KRAS mutations found in roughly a quarter of human tumors, most notably lung, colorectal
  and pancreatic cancer. Its lead program, PT0511, is a pan-KRAS degrader that dosed its first patient in a Phase 1 trial
  in January 2026. The company was co-founded by Nan Ji (Chief Executive Officer) and Huaixiang Hao (Head of Research), with
  Andrew Krivoshik as Chief Medical Officer. PAQ Therapeutics is a therapeutics developer, not a software vendor: it operates
  a four-page corporate WordPress site and publishes no API, SDK, developer portal or machine-readable contract of any kind.'
url: https://raw.githubusercontent.com/api-evangelist/paq-therapeutics/refs/heads/main/apis.yml
deliveryModel:
  model: saas
  open_source: false
  commercial: true
  callable_host: false
  label: Hosted service · you call their endpoint
  confidence: medium
  source:
  - pricing
  generated: '2026-08-28'
  method: derived
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source:
  - security
  generated: '2026-09-02'
  method: derived
image: https://www.paqtx.com/wp-content/uploads/2023/03/paq-therapeutics.jpg
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-08-26'
modified: '2026-08-26'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Oncology
- Therapeutics
- Drug Discovery
- Targeted Protein Degradation
- Life Sciences
- Clinical Stage
- Massachusetts
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: LLMsTxt
  url: llms/paq-therapeutics-llms.txt
- type: DomainSecurity
  url: security/paq-therapeutics-domain-security.yml
- type: Website
  url: https://www.paqtx.com/
- type: Blog
  url: https://www.paqtx.com/news-archive/
- type: BlogRSS
  url: https://www.paqtx.com/feed/
- type: PrivacyPolicy
  url: https://www.paqtx.com/privacy-policy/
- type: TermsOfService
  url: https://www.paqtx.com/terms-and-conditions/
- type: LinkedIn
  url: https://www.linkedin.com/company/paq-therapeutics
x-enrichment:
  date: '2026-08-26'
  status: minimal
  artifacts_added: 3
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: PAQ Therapeutics is a clinical-stage drug developer whose entire public surface is a four-page WordPress marketing
    site — no api., developer., developers., docs. or portal. subdomain resolves in DNS for paqtx.com, and every contract-discovery
    path on www.paqtx.com (/openapi.json, /swagger.json, /graphql, /api-docs, /llms.txt, every /.well-known/*) returns 404.
  evidence:
  - url: https://www.paqtx.com/openapi.json
    status: 404
  - url: https://www.paqtx.com/.well-known/agent-card.json
    status: 404
  - url: https://www.paqtx.com/llms.txt
    status: 404
  - url: https://api.paqtx.com/
    status: 0
  - url: https://www.paqtx.com/
    status: 200
  checked: '2026-08-26'